At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years and legal age of consent
- ✓Histologically or cytologically confirmed SCLC, epNEC (except MCC/MTC/NEPC), or LCNEC of lung
- ✓Mixed histology eligible if neuroendocrine/small cell component ≥50%
- ✓Part 1: SCLC progression after ≥2 prior lines including ≥1 platinum-based regimen
- ✕Untreated or symptomatic brain metastases
- ✕Treated brain metastases allowed only if radiotherapy/surgery ≥2 weeks prior, off steroids ≥7 days, off anti-epileptics ≥7 days or on stable dose
- ✕Leptomeningeal disease
- ✕Parts 2-3: Epidural disease including spinal cord compression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
In Brief
A Phase 2 clinical trial evaluating BI 764532, dose 1 and BI 764532, dose 2 for Small Cell Lung Carcinoma and 2 related conditions. Currently recruiting, targeting 204 participants across 59 sites in 12 countries.
Detailed Summary
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 3 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participants have an equal chance of being in either group. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. In Part 2 and Part 3, all participants receive the same dose of BI 764532. Part 2 and Part 3 are open to people with a certain kind of tumour called extrapulmonary neuroendocrine carcinoma. All participants receive BI 764532 as an infusion into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an overnight stay to monitor participants´ safety. Doctors record any unwanted effects and regularly check the general health of the participants.
Study Details
Timeline
Arms & Interventions
Interventions
BI 764532, dose 1
BI 764532, dose 2